Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using a proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. The Company’s SMNH compounds are small segments of nucleic acids that are designed to selectively target and modulate the activity of specific proteins implicated in various disease states.
Spring Bank is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases. It has designed SB 9200 to selectively activate within infected cells the cellular proteins retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. 

TypePublic
HQHopkinton, US
Founded2002
Size (employees)15 (est)
Websitespringbankpharm.com
Spring Bank Pharmaceuticals was founded in 2002 and is headquartered in Hopkinton, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Spring Bank Pharmaceuticals

Martin Driscoll

Martin Driscoll

Chairman, President and Chief Executive Officer
Nezam Afdhal

Nezam Afdhal

Chief Medical Officer
Jonathan Freve

Jonathan Freve

Chief Financial Officer, Treasurer
Donald Mitchell

Donald Mitchell

Vice President of Operations & Corporate Development
Kevin Leach

Kevin Leach

Vice President, Nonclinical and Translational Research
Garrett Winslow

Garrett Winslow

General Counsel
Show more

Spring Bank Pharmaceuticals Office Locations

Spring Bank Pharmaceuticals has offices in Milford and Hopkinton
Hopkinton, US (HQ)
86 South St
Milford, US
113 Cedar St
Show all (2)
Report incorrect company information

Spring Bank Pharmaceuticals Financials and Metrics

Spring Bank Pharmaceuticals Revenue

USD

Net income (Q3, 2018)

(8.8m)

EBIT (Q3, 2018)

(7.7m)

Market capitalization (9-Nov-2018)

147.4m

Closing stock price (9-Nov-2018)

11.2

Cash (30-Sep-2018)

23.6m
Spring Bank Pharmaceuticals's current market capitalization is $147.4 m.
Annual
USDFY, 2016FY, 2017

General and administrative expense

5.7m8.2m

R&D expense

14.0m13.1m

Operating expense total

19.8m21.3m

EBIT

(19.4m)(21.3m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

General and administrative expense

1.2m1.5m1.5m2.0m1.9m2.0m2.2m2.4m2.1m

R&D expense

5.6m2.9m2.7m2.5m3.4m3.2m4.0m5.6m5.7m

Operating expense total

6.8m4.4m4.2m4.5m5.3m5.2m6.2m8.0m7.7m

EBIT

(6.5m)(4.3m)(4.2m)(4.5m)(5.3m)(5.2m)(6.2m)(8.0m)(7.7m)
Annual
USDFY, 2016FY, 2017

Cash

10.7m23.6m

Accounts Receivable

57.4m

Inventories

840.0k

Current Assets

25.6m51.1m
Quarterly
Annual
USDFY, 2016FY, 2017

Net Income

(17.4m)(27.7m)

Depreciation and Amortization

118.0k158.0k

Inventories

(527.0k)

Accounts Payable

(812.0k)181.0k
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(6.5m)(10.8m)(15.0m)(6.5m)(15.4m)(26.2m)(4.9m)(8.6m)

Depreciation and Amortization

26.0k57.0k87.0k36.0k76.0k115.0k45.0k86.0k

Accounts Payable

(840.0k)(564.0k)148.0k519.0k432.0k254.0k(45.0k)(12.0k)

Cash From Operating Activities

(4.6m)(8.9m)(11.7m)(4.1m)(8.8m)(12.6m)(6.2m)(13.0m)
Show all financial metrics
Report incorrect company information

Spring Bank Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Spring Bank Pharmaceuticals News and Updates

Spring Bank Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences

HOPKINTON, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will present at t…

Spring Bank Pharmaceuticals to Host R&D Day on Thursday, December 6, 2018

HOPKINTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it will host a Research &…

Spring Bank Pharmaceuticals Reports Third Quarter Financial Results

HOPKINTON, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced its 2018 third quarter fi…

Spring Bank Pharmaceuticals, Inc. Appoints Scott Smith to its Board of Directors

Former Celgene President & COO Joins Spring Bank Board
Report incorrect company information

Spring Bank Pharmaceuticals Blogs

Spring Bank Announces Additional Inarigivir Results at AASLD Conference

*Results from full 24 weeks of dosing from the first three cohorts of the ongoing Phase 2 ACHIEVE trial in hepatitis B to be highlighted *New data from ACHIEVE trial demonstrates that increased baseline serum IP-10, a marker of immune activation in HBV, is a positive predictor for anti-viral

Taylor Feehley, Ph.D.

Taylor Feehley, Ph.D. Donna.Al-Beiro… Mon, 10/29/2018 - 10:48 Taylor Feehley, Ph.D. Chardan

Edward Tenthoff

Edward Tenthoff Donna.Al-Beiro… Thu, 10/11/2018 - 13:28 Edward Tenthoff Piper Jaffray

Maury Raycroft, Ph.D.

Maury Raycroft, Ph.D. Donna.Al-Beiro… Thu, 10/11/2018 - 13:26 Maury Raycroft, Ph.D. Jefferies

Spring Bank Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference

HOPKINTON, Mass. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain ca... The post Spring Bank Pharmaceuticals, Inc. t…

Timothy Clackson, Ph.D.

Timothy Clackson, Ph.D. Donna.Al-Beiro… Fri, 09/14/2018 - 10:28 Member of the Compensation Committee Chair of the Science and Technology Committee Timothy Clackson, Ph.D. Director
Show more

Spring Bank Pharmaceuticals Company Life and Culture

Report incorrect company information

Spring Bank Pharmaceuticals Frequently Asked Questions

  • When was Spring Bank Pharmaceuticals founded?

    Spring Bank Pharmaceuticals was founded in 2002.

  • Who are Spring Bank Pharmaceuticals key executives?

    Spring Bank Pharmaceuticals's key executives are Martin Driscoll, Nezam Afdhal and Jonathan Freve.

  • How many employees does Spring Bank Pharmaceuticals have?

    Spring Bank Pharmaceuticals has 15 employees.

  • Who are Spring Bank Pharmaceuticals competitors?

    Competitors of Spring Bank Pharmaceuticals include KemPharm, Achillion Pharmaceuticals and Oxford Biomedica.

  • Where is Spring Bank Pharmaceuticals headquarters?

    Spring Bank Pharmaceuticals headquarters is located at 86 South St, Hopkinton.

  • Where are Spring Bank Pharmaceuticals offices?

    Spring Bank Pharmaceuticals has offices in Milford and Hopkinton.

  • How many offices does Spring Bank Pharmaceuticals have?

    Spring Bank Pharmaceuticals has 2 offices.